The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of two different schedules of nab-paclitaxel (nab-P) with ascending doses of vandetanib (V) with expansion in patients (Pts) with pancreatic cancer (PC).
A. B. El-Khoueiry
Consultant or Advisory Role - AstraZeneca
S. Iqbal
No relevant relationships to disclose
H. Lenz
Consultant or Advisory Role - Abraxis BioScience
B. J. Gitlitz
No relevant relationships to disclose
D. Yang
No relevant relationships to disclose
S. Cole
No relevant relationships to disclose
V. Duddalwar
No relevant relationships to disclose
A. Garcia
No relevant relationships to disclose